Special Issue

Self-Assembled Nanoparticles: An Emerging Delivery Platform for Drugs

Message from the Guest Editors

Due to the small nature of the subunits (10-9 m), nanoparticles often tend to organize in nanostructured self-assemblies. The advantages are myriad; loading of drugs according to morphological requirements can provide versatility, dispersibility in aqueous media can provide stability, the absence of formulation excipients can offer clinical safety and biocompatibility. These processes have gained the attention of researchers and enabled the development of delivery systems for various applications. Since the first success of nanotechnology with the FDA approval of self-assembled liposomes in 1995 for Doxil®, groundbreaking advancement was made very recently when approved for clinical use of mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergence of self-assembling nanoparticle drug delivery systems is advancing rapidly toward clinical use. We welcome articles with a particular focus on addressing state-of-the-art knowledge and future perspectives for the application of self-assembly and the emergence of new approaches for the clinical translation of drug delivery.

Guest Editors

Dr. Pallabita Chowdhury

Plough Center for Sterile Drug Delivery Solutions, The University of Tennessee Health Science Center, 220 S. Dudley Street, Memphis, TN 38104, USA

Prof. Dr. Xiuling Lu

Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT 06269, USA

Deadline for manuscript submissions

closed (20 April 2024)

Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/143344

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals

Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/pharmaceuticals

About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.
We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter
Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

MDPI